SMMT Relative Valuation
SMMT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SMMT is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
52.88
P/B
Median3y
28.78
Median5y
19.86
-0.95
FCF Yield
Median3y
-7.67
Median5y
-13.05
Competitors Valuation Multiple
The average P/S ratio for SMMT's competitors is 299.37, providing a benchmark for relative valuation. Summit Therapeutics Inc Corp (SMMT) exhibits a P/S ratio of 1752.23, which is 485.30% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Summit Therapeutics Inc (SMMT) currently overvalued or undervalued?
What is Summit Therapeutics Inc (SMMT) fair value?
How does SMMT's valuation metrics compare to the industry average?
What is the current P/B ratio for Summit Therapeutics Inc (SMMT) as of Jul 08 2025?
What is the current FCF Yield for Summit Therapeutics Inc (SMMT) as of Jul 08 2025?
What is the current Forward P/E ratio for Summit Therapeutics Inc (SMMT) as of Jul 08 2025?